FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901437794> ?p ?o ?g. }

• W2901437794 endingPage "181" @default.
• W2901437794 startingPage "177" @default.
• W2901437794 abstract "Human epidermal growth factor receptor 2 (HER2) has tyrosine kinase activity and is a member of the epidermal growth factor receptor family. This initiates a variety of signal for pathways which leads to cell proliferation and tumourigenesis. In approximately 15–30% of breast cancers and 10–30% of gastric/gastroesophageal cancers, amplification or overexpression of HER2 occurs, and it serves as a prognostic and predictive biomarker. HER-2/neu is one of the most frequently studied molecular biological parameters in epithelial ovarian cancer (EOC), but its prognostic impact has not been fully assessed. The objective of the current study was firstly to analyse the presence of HER-2 overexpression in EOC patients and secondly to evaluate association between human epidermal growth factor receptor 2 (HER-2/neu) expression and progression-free survival in patients with EOC. In this prospective study of 2 years in our department, 186 gynaecological cancers were operated out of which 98 cases were operated for epithelial ovarian cancer and rest for cervical cancer, endometrial cancer, and other subtypes of ovarian cancer. In this study, HER2 gene status was evaluated in EOC by immunohistochemistry analysis, and overall survival of these patients was evaluated. HER-2 overexpression was found in 22 of the 98 investigated cases (22.45%), in which 14 OC (14.29%) were weakly positive and 8 OC (8.16%) were moderately to intensely positive. In the study, increased HER2 expression was associated with decreased progression-free survival (PFS) and hence poor prognosis (P 0.054). The introduction of HER2-directed therapies has dramatically influenced the outcome of patients with HER2 positive breast and gastric/gastroesophageal cancers. The present study findings provided that HER-2/neu expression in patients with OC has an adverse impact on the PFS. Therefore, our results show that the decision algorithm usually used in breast cancer by HER2 may be appropriate in ovarian cancer." @default.
• W2901437794 created "2018-11-29" @default.
• W2901437794 creator A5001778052 @default.
• W2901437794 creator A5002705130 @default.
• W2901437794 creator A5007780360 @default.
• W2901437794 creator A5029850397 @default.
• W2901437794 creator A5053911139 @default.
• W2901437794 creator A5058674965 @default.
• W2901437794 creator A5069813246 @default.
• W2901437794 creator A5078282589 @default.
• W2901437794 creator A5081371331 @default.
• W2901437794 date "2018-11-21" @default.
• W2901437794 modified "2023-09-27" @default.
• W2901437794 title "Prognostic Value of HER-2/neu Gene Amplification in Epithelial Ovarian Carcinoma" @default.
• W2901437794 cites W1965857816 @default.
• W2901437794 cites W1979538859 @default.
• W2901437794 cites W2003468200 @default.
• W2901437794 cites W2011408267 @default.
• W2901437794 cites W2019925311 @default.
• W2901437794 cites W2037325146 @default.
• W2901437794 cites W2040935952 @default.
• W2901437794 cites W2066263765 @default.
• W2901437794 cites W2084629437 @default.
• W2901437794 cites W2091906134 @default.
• W2901437794 cites W2140401099 @default.
• W2901437794 cites W2154759247 @default.
• W2901437794 cites W2154821327 @default.
• W2901437794 cites W2155587446 @default.
• W2901437794 cites W2158734599 @default.
• W2901437794 cites W2169961966 @default.
• W2901437794 cites W2219978888 @default.
• W2901437794 cites W2569695585 @default.
• W2901437794 doi "https://doi.org/10.1007/s13224-018-1186-5" @default.
• W2901437794 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6801266" @default.
• W2901437794 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31686753" @default.
• W2901437794 hasPublicationYear "2018" @default.
• W2901437794 type Work @default.
• W2901437794 sameAs 2901437794 @default.
• W2901437794 citedByCount "5" @default.
• W2901437794 countsByYear W29014377942020 @default.
• W2901437794 countsByYear W29014377942022 @default.
• W2901437794 countsByYear W29014377942023 @default.
• W2901437794 crossrefType "journal-article" @default.
• W2901437794 hasAuthorship W2901437794A5001778052 @default.
• W2901437794 hasAuthorship W2901437794A5002705130 @default.
• W2901437794 hasAuthorship W2901437794A5007780360 @default.
• W2901437794 hasAuthorship W2901437794A5029850397 @default.
• W2901437794 hasAuthorship W2901437794A5053911139 @default.
• W2901437794 hasAuthorship W2901437794A5058674965 @default.
• W2901437794 hasAuthorship W2901437794A5069813246 @default.
• W2901437794 hasAuthorship W2901437794A5078282589 @default.
• W2901437794 hasAuthorship W2901437794A5081371331 @default.
• W2901437794 hasBestOaLocation W29014377942 @default.
• W2901437794 hasConcept C101544691 @default.
• W2901437794 hasConcept C121608353 @default.
• W2901437794 hasConcept C126322002 @default.
• W2901437794 hasConcept C143998085 @default.
• W2901437794 hasConcept C170493617 @default.
• W2901437794 hasConcept C204232928 @default.
• W2901437794 hasConcept C2776362946 @default.
• W2901437794 hasConcept C2776872082 @default.
• W2901437794 hasConcept C2779438470 @default.
• W2901437794 hasConcept C2780427987 @default.
• W2901437794 hasConcept C2781197716 @default.
• W2901437794 hasConcept C2992773878 @default.
• W2901437794 hasConcept C3019054536 @default.
• W2901437794 hasConcept C502942594 @default.
• W2901437794 hasConcept C530470458 @default.
• W2901437794 hasConcept C55493867 @default.
• W2901437794 hasConcept C71924100 @default.
• W2901437794 hasConcept C84606932 @default.
• W2901437794 hasConcept C86803240 @default.
• W2901437794 hasConcept C98717036 @default.
• W2901437794 hasConceptScore W2901437794C101544691 @default.
• W2901437794 hasConceptScore W2901437794C121608353 @default.
• W2901437794 hasConceptScore W2901437794C126322002 @default.
• W2901437794 hasConceptScore W2901437794C143998085 @default.
• W2901437794 hasConceptScore W2901437794C170493617 @default.
• W2901437794 hasConceptScore W2901437794C204232928 @default.
• W2901437794 hasConceptScore W2901437794C2776362946 @default.
• W2901437794 hasConceptScore W2901437794C2776872082 @default.
• W2901437794 hasConceptScore W2901437794C2779438470 @default.
• W2901437794 hasConceptScore W2901437794C2780427987 @default.
• W2901437794 hasConceptScore W2901437794C2781197716 @default.
• W2901437794 hasConceptScore W2901437794C2992773878 @default.
• W2901437794 hasConceptScore W2901437794C3019054536 @default.
• W2901437794 hasConceptScore W2901437794C502942594 @default.
• W2901437794 hasConceptScore W2901437794C530470458 @default.
• W2901437794 hasConceptScore W2901437794C55493867 @default.
• W2901437794 hasConceptScore W2901437794C71924100 @default.
• W2901437794 hasConceptScore W2901437794C84606932 @default.
• W2901437794 hasConceptScore W2901437794C86803240 @default.
• W2901437794 hasConceptScore W2901437794C98717036 @default.
• W2901437794 hasIssue "S2" @default.
• W2901437794 hasLocation W29014377941 @default.
• W2901437794 hasLocation W29014377942 @default.
• W2901437794 hasLocation W29014377943 @default.
• W2901437794 hasOpenAccess W2901437794 @default.

• next